Lakshmanan Krishnamurti

Dr. Lakshmanan Krishnamurti


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2019 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
DNDonna S. Neuberg
Donna S. Neuberg
KSKeith M. Sullivan
Keith M. Sullivan
NKNaynesh R. Kamani
Naynesh R. Kamani
AAAllistair Abraham
Allistair Abraham
MWMark C. Walters
Mark C. Walters
We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fludarabine (175 mg/m2) and thymoglobulin (6 mg/kg) and cyclosporine or tacrolimus and methotrexate for graft‐vs‐host disease (GVHD) prophylaxis. Twenty‐two patients (median age 22 years; range 17‐36) were enrolled at eight centers. Seventeen patients received marrow from an HLA‐identical sibling donor and five patients received marrow from an 8/8 HLA‐allele matched unrelated donor. Before BMT, patients had stroke, acute chest syndrome, recurrent pain events, were receiving regular red blood cell transfusions, or had an elevated tricuspid regurgitant jet (TRJ) velocity, which fulfilled eligibility criteria. Four patients developed grades II‐III acute GVHD (18%) and six developed chronic GVHD (27%) that was moderate in two and severe in one patient. One patient died of intracranial hemorrhage and one of GVHD. Nineteen patients had stable donor chimerism, 1‐year post‐transplant. One patient who developed secondary graft failure survives disease‐free after a second BMT. The one‐year overall survival and event‐free survival (EFS) are 91% (95% CI 68%‐98%) and 86% (95% CI, 63%‐95%), respectively, and 3‐year EFS is 82%. Statistically significant improvements in the pain interference and physical function domains of health‐related quality of life were observed. The study satisfied the primary endpoint of 1‐year EFS ≥70%. This regimen is being studied in a prospective clinical trial comparing HLA‐matched donor BMT with standard of care in adults with severe SCD (NCT02766465).

3 May 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CSCynthia B. Sinha
Cynthia B. Sinha
NBNitya Bakshi
Nitya Bakshi
DRDiana Ross
Diana Ross
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
Sickle cell disease (SCD) is a chronic multisystem disorder associated with vaso-occlusive pain and organ damage, leading to substantial morbidity, impaired health-related quality of life, substantial health care costs, and a high risk of premature mortality.1 Acute, episodic vaso-occlusive pain may progress to chronic persistent pain2 in more than a third of adults with SCD.2 Opioid analgesics are the mainstay for the management of acute and chronic pain in SCD.2

20 April 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MEMary Eapen
Mary Eapen
RBRuta Brazauskas
Ruta Brazauskas
DWDavid A. Williams
David A. Williams
MWMark C. Walters
Mark C. Walters
AMAndrew St Martin
Andrew St Martin
MHMary M. Horowitz
Mary M. Horowitz
PURPOSE: To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS: Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types included leukemia/myelodysplastic syndrome (MDS; n = 15) and solid tumor (n = 7). Fine-Gray regression models examined for risk factors for leukemia/MDS and any secondary neoplasm. RESULTS: The 10-year incidence of leukemia/MDS was 1.7% (95% CI, 0.90 to 2.9) and of any secondary neoplasm was 2.4% (95% CI, 1.4 to 3.8). After adjusting for other risk factors, risks for leukemia/MDS (hazard ratio, 22.69; 95% CI, 4.34 to 118.66; P = .0002) or any secondary neoplasm (hazard ratio, 7.78; 95% CI, 2.20 to 27.53; P = .0015) were higher with low-intensity (nonmyeloablative) regimens compared with more intense regimens. All low-intensity regimens included total-body irradiation (TBI 300 or 400 cGy with alemtuzumab, TBI 300 or 400 cGy with cyclophosphamide, TBI 200, 300, or 400 cGy with cyclophosphamide and fludarabine, or TBI 200 cGy with fludarabine). None of the patients receiving myeloablative and only 23% of those receiving reduced-intensity regimens received TBI. CONCLUSION: Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.

1 May 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KKKirshma Khemani
Kirshma Khemani
DRDiana Ross
Diana Ross
CSCynthia Sinha
Cynthia Sinha
AHAnn Haight
Ann Haight
NBNitya Bakshi
Nitya Bakshi
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
Sickle cell disease (SCD) is one of the most commonly inherited hemoglobin disorders that has a significant impact on quality of life, increased childhood morbidity, and premature mortality. Currently, hematopoietic stem cell transplant (HSCT) is the only treatment with a curative intent. The objective of this study was to determine patients' and caregivers' knowledge of HSCT, the factors influencing the decision to pursue HSCT, their experiences, and the impact of a successful HSCT on their daily living. At Children's Healthcare of Atlanta, we conducted a qualitative study using a semistructured interview guide of patient-caregiver dyads and 2 focus-group sessions of adult long-term survivors of HSCT to elicit key factors in decision making, their experiences with HSCT, and the impact of HSCT. Interviews and focus-group sessions were recorded and transcribed verbatim. Transcripts were coded and analyzed for emerging themes using NVivo 10.0. We enrolled 11 patient-caregiver dyads (n = 6, female patients; n = 10, mothers) in the qualitative interviews and 2 focus groups with 5 (n = 2, females) and 7 (n = 3, females) participants in each group, respectively. Our analysis revealed 3 prominent themes: (1) factors and concerns influencing HSCT decision making; (2) HSCT experiences; and (3) impact of HSCT on daily life. Participants reported that progression of disease-related complications and availability of a matched donor strongly influenced the decision to pursue HSCT. Although patients and caregivers had to deal with the arduous process of HSCT and transplant-related morbidities, participants were satisfied with their decision and expressed no decisional regrets. Decision making for HSCT for patients with SCD is a complex process. Understanding the key influential factors in decision making and the impact HSCT has on these patients and their families will generate crucial insights that can guide the care of future patients and research studies.

20 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NBNitya Bakshi
Nitya Bakshi
CSCynthia B Sinha
Cynthia B Sinha
DRDiana Ross
Diana Ross
KKKirshma Khemani
Kirshma Khemani
GLGeorge Loewenstein
George Loewenstein
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
Sickle cell disease (SCD) is an inherited blood disorder that primarily affects African-American and other ethnic minority populations. There are three available disease-modifying therapies for sickle cell disease: hydroxyurea (HU), bone marrow transplantation (BMT), and chronic blood transfusion (CBT). Since these treatments vary in their therapeutic intent, efficacy in preventing progression of the disease, short and long-term adverse effects, costs and patient burden, the decision-making process regarding these therapies is complicated for both the patient and healthcare provider. While previous research has focused on the patient perspective of treatment-related decision making, there is a paucity of research investigating the physician perspective of treatment-related decision making. We conducted a qualitative study with physicians who were experts in the field of SCD. Interviews focused on physician perceptions of patient decisional needs as well as physicians’ approach to decision making regarding disease-modifying therapies in SCD. Thirty-six physician interviews were analyzed, with a focus on their perspectives regarding available treatment options and on how they approach decision making with patients. We identified two narrative approaches. The Collaborative approach (CA) was characterized by emphasizing the need to discuss all possible treatment options to ensure that the patient and/or family was equipped to make an informed decision. The Proponent approach (PA) was characterized by strongly advocating a pre-determined treatment plan and providing patients/families with information, with the objective of convincing them to accept the treatment. An interplay of patient-related and disease-related factors, decision type and physician-related factors, as well as institutional frameworks, influenced physician perspectives on treatment options and decision making regarding these therapies. These findings point to the potential value of developing systems to foster patient engagement as a way of facilitating shared decision making.

13 May 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JTJohn F. Tisdale
John F. Tisdale
FPFrancis J. Pierciey
Francis J. Pierciey
MBMelissa Bonner
Melissa Bonner
ATAlexis A. Thompson
Alexis A. Thompson
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
MWMark C. Walters
Mark C. Walters
Click on the article title to read more.